Filing Flows › AbCellera Biologics (ABCL) › Q2 2025
AbCellera Biologics (ABCL) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
AbCellera Biologics (ABCL) reported revenue of $17.1M for the second quarter 2025 (Q2 2025), +133% from a year earlier and +303% from the quarter before. Operating margin was -290.2%, net loss $34.7M (203.3% of revenue).
AbCellera Biologics, Q2 2025: revenue $17.1M (+133% year over year), operating margin -290.2%, net loss $34.7M, operating cash flow −$32.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $17.1M | +303% | +133% |
| Operating profit | −$49.6M | — | — |
| Net earnings | −$34.7M | — | — |
| Operating cash flow | −$32.4M | — | — |
What changed
Revenue was $17.1M in Q2 2025, up 133% year over year and up 303% from the previous quarter. Licensing revenue was the largest line at 61% of revenue. Licensing revenue added $10.1M year over year (up 2723%), 103% of the total change.
Operating costs exceeded revenue by $49.6M, an operating margin of -290.2%. Total costs fell 34% while revenue rose 133%. The quarter ended with a net loss of $34.7M, narrower than the previous quarter's $45.6M loss. Non-operating items added $13.2M, -36% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$32.4M. Non-cash charges added back $5.5M of depreciation and amortization and $14.2M of share-based compensation. Working capital and other items used $17.4M. Capital expenditures of $13.4M exceeded it, leaving free cash flow of −$45.8M.
Questions
What was AbCellera Biologics' revenue in the second quarter 2025?
AbCellera Biologics (ABCL) reported revenue of $17.1M for the second quarter 2025 (Q2 2025), +133% from a year earlier and +303% from the quarter before.
Was AbCellera Biologics profitable in the second quarter 2025?
Operating loss was $49.6M (-290.2% of revenue) and net loss $34.7M.